Navigation Links
Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
Date:12/19/2011

e deacetylase inhibitors for which broad patent applications are also pending. The Company is targeting treatments for several types common and rarer but devastating cancers. The primary emphasis is on the most common and most aggressive type of brain cancer of adults, glioblastoma multiforme and other cancers of neural tissue (nerve and brain), including medulloblastoma, the most common brain tumor of children, and neuroblastoma, the most common cancer of children, as well as non-neural cancers of adults, including breast and pancreatic cancer, melanomas and sarcomas. 

Forward-Looking Statements
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Fac
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
2. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
5. Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
6. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
10. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... will participate in the upcoming 27 th Annual ... Dana Point, CA.  Dr. Michael ... Oramed, will present a corporate overview on March 10, ...
(Date:3/4/2015)... Mallinckrodt plc (NYSE: MNK ), a ... Global Healthcare Conference at the Loews Miami Hotel in ... 11, 2015. Mark Trudeau, President and Chief Executive Officer of ... to begin at 10:45 a.m. Eastern. Individuals ... webcast information on Mallinckrodt,s Investor Relations website ...
(Date:3/4/2015)... NEWARK, N.J. , March 4, 2015 /PRNewswire/ ... biopharmaceutical company developing innovative medicines for serious women,s ... 1 clinical program demonstrating that its lead product ... had predictable pharmacokinetics (PK), and that contraceptive efficacy ... by SYM-1219 administration. These results will ...
Breaking Medicine Technology:Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3Mallinckrodt to Present at Barclays Conference March 11 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5
... MedShape Solutions, Inc., the industry leader in innovative ... developed new, larger sizes of its ExoShape CL, ... simplifies and improves soft tissue graft fixation during ... comes after MedShape received the U.S. Food and ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced that ... the ongoing Phase Ia trial to test the safety of ... testing the drug in healthy volunteers for safety and tolerability. ... that stimulates new neuron growth in the hippocampus, an area ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... downstream client survey, marketing channels, industry development trend ... of the industry, including spices definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:3/4/2015)... GA (PRWEB) March 04, 2015 ... advanced microfiber technology and their first compression therapy collection ... success of this collection, SIGVARIS USA is proud to ... MIDTOWN MICROFIBER product line. , Constructed from a unique, ... all-day comfort in mind. These socks and thigh-highs offer ...
(Date:3/4/2015)... In a small ceremony with 20 attendees ... new facility in New Port Richey on February 24, 2015 ... will allow the Florida drug detox facility to ... epidemic through treatment and education. “Due to our unique medical-detox ... United States, we made the decision that expanding our facility ...
(Date:3/4/2015)... Today Visiopharm announces that Patrik Dahlén, previously the ... Visiopharm Board of Directors as Chairman. Mr. ... positioned to become the fastest growing software company, specializing ... , "Over the last several years, Visiopharm ... ONCOtopix™ Dx, a complete quantitative digital pathology solution for ...
(Date:3/4/2015)... A new dieting routine, called the ... of extending life. Studies conducted by the ... routine can help extend life by increasing anti-oxidant production. ... term benefits, many suffering from obesity are already experiencing ... necessary. As an alternative to the new Feast and ...
Breaking Medicine News(10 mins):Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3
... US June 17, 2008 Shire Limited (LSE: ... announced the publication of data from a randomized, long-term ... (UC) drug Lialda™ (mesalamine). The primary endpoints of this ... Lialda in mild-to-moderate UC patients over 12 months. Data ...
... to the 54th Summer Fancy Food Show in New York City from ... ... 17 WORLDFOODS provides the perfect,product for those with food allergies, are ... lose out on,great taste. WORLDFOODS offers an exciting variety of 59 types ...
... in Supporting,Progressive, Financially Sound and Effective Healthcare Solutions, ... Blue and Yellow Ribbons on,June 19, NASHVILLE, ... patients in Tennessee to have ready access to ... Bredesen, for the,second consecutive year, has declared June ...
... Kimberly-Clark Professional is,donating thousands of health and hygiene ... up from the extensive damage caused by the,recent ... very hard by these storms and the,flooding that ... North America. "At Kimberly-Clark,Professional, our mission is to ...
... and Bags Provide Perfect Medium for Showing Support and, Generating ... ... of Death, SAN MATEO, Calif., June 17 CafePress, the ... the newly launched Stand Up To Cancer initiative, to raise money ...
... AHIP Institute July 18-20, WASHINGTON, June 17 ... for health plans and health networks wrestling with,market ... outsourcing of,credentialing services., (Logo: http://www.newscom.com/cgi-bin/prnh/20030501/URACLOGO ... the AHIP Institute, June 18-20,in San Francisco. URAC ...
Cached Medicine News:Health News:Long-term safety data on Lialda published in leading GI journal 2Health News:Long-term safety data on Lialda published in leading GI journal 3Health News:WORLDFOODS Provides All Natural Authentic Asian Sauces That Cater to Vegetarians, Celiacs and Those With Food Allergies 2Health News:Governor Bredesen Declares Tennessee Patient Advocacy Day to Promote Healthcare Accessibility for All 2Health News:Governor Bredesen Declares Tennessee Patient Advocacy Day to Promote Healthcare Accessibility for All 3Health News:CafePress Supports Stand Up To Cancer With Online Store to Help Raise Awareness and Funds for Research 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 3
... the High Performance line, Zebra's 110XiIIIPlus is a ... hardworking printer is the one to call on ... available with either 4.09 inch (104 mm) or ... that best meets your needs, either 200, 300, ...
... tested XiIIIPlus platform, the R110Xifor four-inch ... on-demand printing flexibility in tag placement ... as XML for seamless integration into ... positioning, multiple power levels, statistics tracking, ...
... prints labels up to 8.5 ... It is ideal for wide ... chemical drum labels, primary metal ... banner-sized labels and pallet and ...
... CareChek Tx, which has received ... device for blood transfusions, allows ... patient to the unit of ... administering a transfusion.The system can ...
Medicine Products: